OCTP update from Doceo

Oxford Cannabinoid Technologies Holdings plc (OCT) have launched new video content with Doceo.

Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines for approval by global regulatory agencies and targeting the US$ multi-billion pain market, is pleased to announce a new video on Doceo.

OCT is a dynamic biotechnology company aiming to revolutionise drug development by utilising a diverse range of compounds, including proprietary cannabinoid derivatives, natural phytocannabinoids, and innovative new chemical entities (NCEs) that target the endocannabinoid system. Their strategic approach ensures the creation of a drug development portfolio that maximises the therapeutic potential of cannabinoids, while also driving long-term market value and market exclusivity in all activities.

For an update on OCT, visit: https://doceo.tv/funds/oxford-cannabinoid-technologies/. For further information on Doceo please visit www.doceo.tv or contact the team on [email protected]